Alzheimer’s drug studied in R.I. heads to FDA for approval

BUTLER HOSPITAL along with Rhode Island Hospital contributed the highest number of participants in clinical trials for aducanumab, an investigational drug for the treatment of Alzheimer’s disease. / COURTESY BUTLER HOSPITAL
PROVIDENCE – An investigational Alzheimer’s disease drug studied extensively in Rhode Island has been submitted to the U.S. Food and Drug Administration for approval. The drug, aducanumab, was administered to participants in clinical trials across the country, including at Butler Hospital and Rhode Island Hospital. The two hospitals contributed the highest number of participants in…

Want More?

Subscribe or register with Providence Business News to keep reading.

REGISTER
for 2 more stories

Subscribe now for $1 for 4 weeks
Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

- Advertisement -

No posts to display